FDA Greenlights Higher-Dose Wegovy 7.2 mg as Novo Nordisk Fights Back Against Zepbound Dominance The weight-loss drug wars just heated up. The U.S. Food and Drug Administration has approved Novo Nordisk’s higher-dose version of Wegovy — a 7.2-milligram injection — giving the blockbuster semaglutide shot a fresh edge against rival Eli Lilly’s Zepbound. Novo plans … Read more
Eli Lilly to Unveil Trial Data for Oral Weight Loss Drug Orforglipron [City, Date] – Pharmaceutical giant Eli Lilly is set to release highly anticipated clinical trial data for its experimental oral weight loss drug, orforglipron, as the race to dominate the booming obesity treatment market intensifies. The upcoming data could position the company as … Read more
Trump Indicators Pharmaceutical Tariffs Are Coming, But Shares Rise in Defiance April 9, 2025 – Washington, D.C. – President Donald Trump doubled down on his commerce warfare rhetoric Tuesday night time, declaring at a Nationwide Republican Congressional Committee dinner that “main” tariffs on pharmaceutical imports are imminent, a transfer he insists will “carry drug manufacturing … Read more
Eli Lilly’s Obesity Pill Orforglipron Challenges Novo Nordisk’s Oral Wegovy in Weight-Loss Market Race August 24, 2025 The obesity drug market, projected to surpass $73 billion by 2034, is witnessing a fierce competition between pharmaceutical giants Eli Lilly and Novo Nordisk. Eli Lilly’s oral GLP-1 receptor agonist, orforglipron, is emerging as a significant rival to … Read more